Baseline glucose-to-lymphocyte ratio predicts nivolumab outcomes in advanced non-small cell lung cancer: a multicenter retrospective study.

Front Immunol · 2026 · PMC12936015 · PMID 41766853

Europe PMC DOI

hedged sentence

0.1360

closest p · 2.7× alpha

0.1360

boldest claim

The sentences

did not reach statistical significancep = 0.136not close (p > 0.1)

A baseline GLR ≥70.76 was independently associated with worse OS (HR 1.79, 95% CI: 1.48–2.16; p < 0.001), but did not reach statistical significance for PFS (HR 1.22, 95% CI: 0.94–1.58; p = 0.136).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.